Phase 3 Clinical Trials With Primary Completion Dates in January 2024
This is a list of Phase 3 trials with primary completion dates in January 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2024-01-01 | Phase 3 | NCT04531982 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia |
| ALVR | AlloVir, Inc. | 2024-01-01 | Phase 3 | NCT05179057 | Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation |
| CING | Cingulate Inc. | 2024-01-01 | Phase 3 | NCT05924594 | Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 |
| MRNS | Marinus Pharmaceuticals, Inc. | 2024-01-01 | Phase 3 | NCT05323734 | Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy |